Background: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH. Methods: Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible. Those with incomplete or miscoded data were excluded. Khorana scores were calculated based on the pretreatment data and categorized into high (3) or intermediate (1-2) VTE risk. Other patient-, tumor-, and therapy-related factors were also analyzed. The w 2 and logistic regression analyses were used to assess differences in VTE rates based on the clinical characteristics. Subgroup analyses were performed to evaluate the Khorana score and associated variables for early (<3 months) and late (>3 months) VTE. Results: A total of 943 patients were eligible for analysis. The cumulative VTE rate was 9.9%. There was no statistical difference in overall VTE rate between Khorana high-and intermediate-risk groups (P ¼ .16). In the multivariate analysis, nonurothelial histology (odds ratio [OR] ¼ 2.56; P ¼ .002) and the presence of cardiovascular disease (CVD) or CVD risk factors (OR ¼ 2.14; P ¼ .002) were associated with increased VTE risk. In the first 3 months from initiation of chemotherapy, Khorana high risk (OR ¼ 2.08; P ¼ .04) was associated with higher VTE rates. White blood cell (WBC) count (OR ¼ 1.05; P ¼ .04) was the only significant Khorana variable for early VTE. Conclusions: The Khorana score stratifies early but not overall VTE risk in patients with metastatic UC/VH. The WBC count drives the increased early VTE risk seen with the Khorana score.
Introduction
Venous thromboembolism (VTE) is a common complication in the management of patients with cancer and is associated with increased morbidity and mortality. [1] [2] [3] Compared to the general population, patients with cancer are at a 4-to 7-fold increased risk of developing a VTE. 3 However, the risk of developing a VTE is not uniform across all patients and is dependent on various patient-, tumor-, and treatment-related factors. Nonetheless, individual risk factors alone are insufficient to identify a high-risk population who may benefit from primary thromboprophylaxis.
The Khorana score is a predictive risk assessment model for VTE in patients with cancer. 4 Khorana et al identified 5 variables predictive for VTE: primary tumor site, body mass index, white blood cell (WBC) count, platelet count, and hemoglobin level or use of erythropoiesis-stimulating agents. 4 The risk model then categorized patients into low (0), intermediate (1) (2) , or high risk (3) , based on these variables. Subsequently, the Khorana score was validated in the Vienna Cancer and Thrombosis Study (CATS), a prospective, observational cohort study of 819 patients representing 10 different malignancies. 5 Although the Khorana score is now a validated tool to stratify VTE risk in patients with cancer, urothelial carcinoma and variant histologies (UC/VH) were not well represented in these studies. In the original analysis, patients with bladder cancer were grouped into the ''other'' category, which only represented 10% of the study population. 4 Moreover, in the CATS study, patients with UC/VH were not included in the analysis altogether. 5 Yet, patients with genitourinary malignancies (excluding prostate cancer) are considered at ''higher risk'' and receive 1 point in the risk model. In this study, we sought to evaluate whether the Khorana score predicted for VTE in patients with metastatic UC/VH treated with systemic chemotherapy.
Methods

Study Design and Patient Population
The Retrospective International Study of Cancers of the Urothelium (RISC) is a multicenter, international retrospective study of the management and outcomes of patients who develop at least muscle-invasive UC/VH. Clinical data were extracted from patient charts and compiled via a passwordprotected data capture platform from 29 international academic centers with previously described methods. 6 All participating institutions were granted approval by their respective institutional review boards.
Patients diagnosed with metastatic disease of the bladder, urethra, or upper urinary tract (renal pelvis or ureter) who were subsequently treated with systemic chemotherapy were eligible for analysis. All patients were required to have complete information on all the Khorana score variables for inclusion in the analysis. Patients with miscoded data were excluded. Any patient without a date of diagnosis of metastatic disease or VTE data was also excluded. The VTE incidence stratified by Khorana risk group was the primary end point of this analysis. A VTE was defined as a deep vein thrombosis, pulmonary embolism, catheter-associated thrombosis, or other venous thrombosis (eg, splanchnic vein thrombosis); all diagnoses were assigned by local investigators without central radiographic adjudication. Khorana scores were calculated based on pretreatment data and categorized into high (3) or intermediate (1-2) VTE risk. Low VTE risk score was not possible given the 1 point mandatory assignment for all patients in this analysis for their primary tumor site. Additionally, each individual Khorana score variable was independently assessed.
Other patient-, tumor-, and treatment-related factors were evaluated for their association with VTE risk. We have previously reported from the RISC database that nonurothelial histology, the presence of cardiovascular disease (CVD; coronary artery disease, peripheral vascular disease, or a cerebrovascular accident) or CVD risk factors (hypertension, diabetes mellitus, or hyperlipidemia), and renal dysfunction are associated with development of a VTE in the metastatic setting. 7 Given that the patient cohort for this analysis is a subset of the prior study, these clinical characteristics were chosen a priori to be included in the multivariate analysis. Comorbidities captured in the database were derived from the Charlson comorbidity index. 8 Those with at least 2% prevalence were further assessed for their association with VTE. Age, gender, race, primary tumor location, and primary tumor treatment with either surgery or radiotherapy were also evaluated.
Lastly, since the median follow-up in the development and validation cohorts of the Khorana score was 73 days, we hypothesized that the Khorana score may be more effective in predicting early VTE risk. 4 Therefore, we performed a subgroup analysis of Khorana high or intermediate risk stratified by early (within the first 3 months) and late (after 3 months) VTE development following initiation of systemic chemotherapy.
Statistical Analysis
Cumulative VTE incidence was calculated from the time of initiation of first-line chemotherapy. For the univariate analysis, w 2 and Fisher exact tests were used to evaluate differences in VTE rates when assessing categorical independent variables. When evaluating VTE rates based on continuous independent variables in the univariate analysis, simple logistic regression was applied. Khorana risk groups, a priori identified clinical characteristics, demographic variables (ie, age, gender, and race), and any statistically significant independent covariates in the univariate analysis (P .05) were planned to be included in the multivariate logistic regression model. The subgroup analyses were carried out using the same multivariate logistic regression model.
Results
Study Population and Patient Characteristics
Of the 3025 patients who comprise the RISC database, 1912 developed metastatic disease ( Figure 1 ). Of these, 484 did not receive chemotherapy in the metastatic setting, and 485 had incomplete or miscoded data. Therefore, 943 patients were eligible for analysis. The baseline patient characteristics of the study cohort are shown in Table 1 . The mean age was 66.0 years. Most patients' primary tumor was located in the bladder (82.4%), and the most common histologic subtype was urothelial (91.5%).
Cumulative Incidence of VTE and Association With Clinical Characteristics
Unadjusted VTE incidence rates based on patient demographics and clinical characteristics are shown in Table 2 . In all, there were 93 VTEs for a cumulative incidence of 9.9%. The VTE incidence rates for the high-and intermediate-risk groups were 13.0% (95% confidence interval [CI]: 8.2%-19.1%) and 9.2% (95% CI: 7.3%-11.5%), respectively. However, there was no statistically significant difference in cumulative VTE incidence between the 2 groups (P ¼ .15). Additionally, none of the independent Khorana score variables were associated with increased VTE risk. Nonurothelial histology (P < .001), the presence of CVD or CVD risk factors (P ¼ .001), and renal dysfunction (P ¼ .03) were associated with the development of a VTE, as previously reported. 7 No other clinical characteristics assessed achieved statistical significance in the univariate analysis.
Multivariate Analysis of Clinical Characteristics and VTE
As previously reported, 7 on multivariate analysis, nonurothelial histology (odds ratio [OR] ¼ 2.56; 95% CI: 1.40-4.70; P ¼ .002) and CVD or CVD risk factors (OR ¼ 2.14; 95% CI: 1.31-3.48; P ¼ .002) were associated with an increased incidence of VTE ( independently, only WBC count (OR ¼ 1.05; 95% CI: 1.00-1.10; P ¼ .04) was associated with a higher frequency of early VTE.
Discussion
The Khorana score was developed to improve stratification of VTE risk in ambulatory patients with cancer planning on receiving chemotherapy. 4 One potential application of the Khorana score is to identify a subset of patients with cancer at particularly high risk of VTE for enrollment in prospective primary thromboprophylaxis studies. Two randomized clinical trials of primary thromboprophylaxis in multiple solid tumors have demonstrated a statistically significant decrease in VTE rates. 9,10 However, the absolute benefit from thromboprophylaxis was only approximately 2% in both studies, with the placebo group in both studies having a VTE rate of less than 4% at a median follow-up of 3.5 months. Consequently, primary thromboprophylaxis has not been adopted into routine clinical practice nor recommended by consensus guidelines for VTE prevention. 11, 12 In their original analysis, Khorana et al demonstrated that patients with a high-risk score had a VTE rate of 7.1% and 6.7%, whereas the intermediate-risk score patients had a VTE rate of 1.8% and 2.0% in the development and validation cohorts, respectively. 4 Subsequently, the CATS study showed a VTE incidence rate of 17.7% at 6 months in patients with a high-risk Khorana score. 5 These studies suggest that patients with high-risk Khorana scores may be ideal for clinical trial enrollment in primary thromboprophylaxis studies.
In our patient cohort, there was no statistically significant difference in overall VTE rates between Khorana high-and intermediate-risk patients. However, when we evaluated the Khorana score's ability to predict early VTE risk, the Khorana score was able to stratify VTE risk in patients with metastatic UC/VH. In the first 3 months, patients with metastatic UC/VH with a high-risk Khorana score had a VTE rate of 8.0%, comparable to the VTE rate in the original Khorana analysis and higher than the rates seen in unselected randomized clinical trials. Therefore, the Khorana score could be used to identify patients with metastatic UC/VH who could be candidates for primary thromboprophylaxis clinical trials.
The Khorana score's ability to predict for early VTE may come as a result of the variables in the model also being prognostic for worse outcomes. For example, a hemoglobin level <10 g/dL has been validated as a poor prognostic factor in patients with metastatic UC who have progressed on platinum-based chemotherapy. 13 Of all the Khorana variables, leukocytosis has the strongest evidence for association with early mortality. Connolly et al reported that patients with leukocytosis initiating chemotherapy had a 2.2-fold increased risk of early mortality, with a median time to death of 38 days. 14 Furthermore, a case series of 9 patients with UC with unexplained leukocytosis and neutrophilia demonstrated a median overall survival of 71 days from the development of leukocytosis to death. 15 Thus, early VTE may be associated with aggressive disease, and patients with late VTE may have a better prognosis malignancy, with VTE likely driven by other factors.
In our multivariate analysis, the only Khorana risk score variable found to be significantly associated with increased risk for early VTE was WBC count. The mechanism underlying the association of leukocytosis, neutrophilia, and VTE is unclear. One possible explanation is through tumor-derived granulocyte colony-stimulating factor (G-CSF) leading to production of neutrophilic extracellular traps (NETs). 16 NETs are released from highly activated neutrophils and shown to be harmful to the vasculature through promotion of thrombus formation by providing the nidus for platelet adhesion, activation, and aggregation. 17, 18 Furthermore, in a G-CSF producing mouse model of mammary carcinoma, administration of G-CSF neutralizing antibody reduced the peripheral blood neutrophil count and the ability of neutrophils to undergo NET generation, suggesting that activation of neutrophils with G-CSF is important for NET formation. 19 Lastly, NET formation coincided with development of venous thrombi in the lung. Taken together, these studies suggest that NETs may play a role in VTE development in patients with cancer with leukocytosis and neutrophilia. There were several limitations to our study. First, the study is limited by its retrospective nature and the inherent confounders associated with such analyses. In addition, clinical characteristics that may predispose patients to VTE, such as poor Eastern Cooperative Oncology Group (ECOG) performance status or inherited thrombophilia, had significant missing data and were not included in the analysis. Although VTE for this analysis used a uniform definition, each event was ascribed by an independent investigator, and central radiographic adjudication was not performed. Finally, the ability to find statistical significance in some of our variables in the early and late subgroup analyses may have been limited by absolute incidence rates for patients with specific variables, in particular renal dysfunction.
In summary, the Khorana score does not adequately stratify cumulative VTE risk in patients with metastatic UC/VH overall. However, it appears to be able to predict early VTE, thus, it is reasonable to use the Khorana score to identify a high-risk population for a primary thromboprophylaxis clinical trial of patients initiating the first-line chemotherapy. However, it is possible that the reason the Khorana score is able to predict for early VTE is because the variables within the model also likely predict for early mortality, and VTE may be associated with poor prognosis disease. Finally, in patients with metastatic UC/VH, further investigation into the association between leukocytosis and VTE should be undertaken to better understand and treat the underlying biological mechanism.
